Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

What did Pope John Paul II, Ronald Reagan and Robin Gibb of the Bee Gees have in common? Each was diagnosed with colorectal cancer, the third most commonly diagnosed cancer in the world and the fourth most common cause of cancer death.

29 Jan 2013

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

BioInvent International announced today the first results from the BI-505 phase I study in patients with multiple myeloma.

24 Jan 2013

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced positive, statistically significant data from the Company's Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb (also referred to as SPI-014) in healthy volunteers.

8 Jan 2013

Rhythm commences RM-493 Phase 2 trial in obesity

Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity.

7 Jan 2013

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Celtaxsys, Inc., a private biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders, today announced the initiation of a first-in-human Phase 1 clinical study of CTX-4430, which blocks the pro-inflammatory enzyme Leukotriene A4 Hydrolase (LTA4H).

3 Jan 2013

$Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer$

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.

3 Jan 2013

Kareus announces start of KU-046 Phase I study in Alzheimer's

Kareus Therapeutics SA, the private biotechnology company focused on the development of novel therapeutics for the unmet treatment of age-related and chronic diseases, today announces the start of a Phase I clinical study following the Investigational New Drug (IND) approval from the US Food and Drug Administration for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer's disease using Kareus' proprietary bioenergetics and KARLECT platforms.

3 Jan 2013

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.

21 Dec 2012

Biotest receives FDA approval for BIVIGAM to treat primary humoral immunodeficiency

Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for BIVIGAM for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA).

20 Dec 2012

Riverside Methodist Hospital treats first PAD patient with Cook Medical's Zilver PTX device

Just weeks after the Food and Drug Administration (FDA) approved Cook Medical's Zilver PTX Drug-Eluting Peripheral Stent, Riverside Methodist Hospital in Columbus, Ohio, has treated the first patient with the device as part of Cook's U.S. commercial launch.

19 Dec 2012

e-Therapeutics’ ETS2101 cancer trials on track

e-Therapeutics plc today provides an update on the clinical trials of its cancer drug ETS2101. Two phase I studies, one in patients with primary or secondary brain cancer and the other in patients with various solid tumours, remain on track to report final data in Q4 2013 and Q1 2014, respectively. Interim data from the trials are expected in H1 2013.

18 Dec 2012

Concern over enoxaparin bleeding risk in patients with moderate renal impairment

The low molecular weight heparin enoxaparin is associated with an increased risk for major bleeding in patients who have moderate renal impairment, say US scientists in findings that have prompted calls for updates to dosing recommendations.

14 Dec 2012

Interim results from Inspiration’s OBI-1 and IB1001 hemophilia clinical study

Inspiration Biopharmaceuticals, Inc. (Inspiration) announced interim clinical results for the company's two lead product candidates, an intravenous recombinant porcine FVIII (OBI-1) in the treatment of serious bleeds in acquired hemophilia A (AHA) and an intravenous recombinant FIX (IB1001) for the treatment and prevention of bleeding in children less than 12 years of age with hemophilia B.

13 Dec 2012

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the results of its successful Phase 2 clinical trial evaluating an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women has been published online by Bone, the Official Journal of the International Bone and Mineral Society.

13 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

uniQure commences acute intermittent porphyria Phase I clinical trial

uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient.

11 Dec 2012

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced new data from its ongoing Phase 1, open-label, dose-escalation trial of IPI-145, the company's potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with advanced hematologic malignancies.

11 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Pharmacokinetics News and Research

Further Reading

Oncolytics Biotech reports new findings at ASCO’s 2013 Gastrointestinal Cancers Symposium

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Rhythm commences RM-493 Phase 2 trial in obesity

Celtaxsys commences CTX-4430 Phase 1 study to treat pulmonary inflammation

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Kareus announces start of KU-046 Phase I study in Alzheimer's

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

Biotest receives FDA approval for BIVIGAM to treat primary humoral immunodeficiency

Riverside Methodist Hospital treats first PAD patient with Cook Medical's Zilver PTX device

e-Therapeutics’ ETS2101 cancer trials on track

Concern over enoxaparin bleeding risk in patients with moderate renal impairment

Interim results from Inspiration’s OBI-1 and IB1001 hemophilia clinical study

Unigene announces results from oral PTH Phase 2 study on osteoporosis

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Janssen announces U.S. prescribing information update for EDURANT tablets

uniQure commences acute intermittent porphyria Phase I clinical trial

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Industry Focus - Biopharma eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News